Literature DB >> 17181481

Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.

Radek Spisek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17181481     DOI： 10.1586/14737140.6.12.1689

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  3 in total

1.  Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Authors:  Michal Podrazil; Rudolf Horvath; Etienne Becht; Daniela Rozkova; Pavla Bilkova; Klara Sochorova; Hana Hromadkova; Jana Kayserova; Katerina Vavrova; Jan Lastovicka; Petra Vrabcova; Katerina Kubackova; Zdenka Gasova; Ladislav Jarolim; Marek Babjuk; Radek Spisek; Jirina Bartunkova; Jitka Fucikova
Journal:  Oncotarget       Date:  2015-07-20

2.  First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.

Authors:  Neil L Berinstein; Mohan Karkada; Michael A Morse; John J Nemunaitis; Gurkamal Chatta; Howard Kaufman; Kunle Odunsi; Rita Nigam; Leeladhar Sammatur; Lisa D MacDonald; Genevieve M Weir; Marianne M Stanford; Marc Mansour
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531

Review 3.  Therapeutic vaccines and cancer: focus on DPX-0907.

Authors:  Mohan Karkada; Neil L Berinstein; Marc Mansour
Journal:  Biologics       Date:  2014-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.